Two hormone systems instead of one changes how the body responds
Em junho de 2025, o Brasil recebe um novo capítulo na história do tratamento da obesidade e do diabetes: o Mounjaro, nome comercial da tirzepatida, chega às farmácias com um mecanismo de ação que vai além do que os medicamentos dominantes oferecem. Enquanto Ozempic e Wegovy atuam sobre uma única via hormonal, a tirzepatida aciona dois sistemas simultaneamente, sugerindo que a complexidade da biologia humana pode exigir abordagens igualmente complexas. Estudos publicados em periódicos de referência apontam resultados superiores de perda de peso, mas a medicina sabe que toda novidade carrega perguntas que só o tempo responde.
- A chegada do Mounjaro ao Brasil em 7 de junho reacende o debate sobre qual medicamento para obesidade oferece de fato a melhor relação entre eficácia e segurança.
- Com preço de R$ 3.627,82 por dose, o acesso ao novo tratamento permanece restrito a uma parcela pequena da população, ampliando a tensão entre inovação médica e equidade.
- Estudos do JAMA mostram que a tirzepatida supera a semaglutida em percentuais de perda de peso, enquanto Ozempic e Wegovy acumulam alertas sobre possíveis efeitos adversos na visão.
- Médicos endocrinologistas precisam reaprender a lógica de prescrição: Mounjaro e Ozempic são indicados para diabetes, enquanto Wegovy se destina à obesidade sem diabetes — distinções que afetam cobertura e expectativas.
- O verdadeiro veredicto sobre o Mounjaro não virá nos primeiros meses de disponibilidade, mas nos anos seguintes, quando os dados de longo prazo revelarão quem se beneficia mais de qual abordagem.
Um novo medicamento para diabetes e obesidade chega ao Brasil em junho, e sua diferença em relação aos fármacos que dominaram os últimos dois anos não é apenas de marketing — é de mecanismo. O Mounjaro, nome comercial da tirzepatida, estará disponível nas farmácias a partir de 7 de junho, ao preço de R$ 3.627,82 por dose.
Ozempic e Wegovy são, na essência, o mesmo composto: a semaglutida, que age sobre a via hormonal GLP-1, responsável por sinalizar ao cérebro a sensação de saciedade. O Mounjaro vai além: é um agonista duplo, ativando simultaneamente o GLP-1 e o GIP, hormônio que regula a liberação de insulina durante a digestão. Ao acionar dois sistemas ao mesmo tempo, a tirzepatida produz um efeito fisiológico distinto.
As evidências clínicas sustentam essa diferença. Um estudo publicado no JAMA Internal Medicine em julho de 2024 comparou diretamente os dois medicamentos em pacientes com excesso de peso e favoreceu o Mounjaro em todos os indicadores: maior percentual de peso perdido e mais pacientes atingindo reduções consideradas significativas. Em paralelo, outro estudo no JAMA Ophthalmology associou Ozempic e Wegovy a possíveis problemas de visão — efeito adverso menos documentado na abordagem de dupla ação.
A médica Melissa Barcellos Azevedo, chefe do serviço de endocrinologia do Hospital Mãe de Deus em Porto Alegre, esclarece as distinções práticas: Ozempic e Wegovy são intercambiáveis em princípio ativo, diferindo apenas na dose e na indicação — diabetes ou obesidade sem diabetes. O Mounjaro pertence a uma classe diferente, com lógica de prescrição própria.
A chegada do novo medicamento não substitui os anteriores, mas amplia as opções disponíveis para médicos e pacientes. A pergunta sobre qual abordagem funciona melhor para cada organismo só encontrará resposta completa nos anos à frente, à medida que os dados de longo prazo se acumularem.
A new medication for diabetes and obesity is arriving in Brazil this June, and it works differently than the drugs that have dominated conversations about weight loss over the past two years. Mounjaro, the brand name for tirzepatida, will hit Brazilian pharmacies on June 7 at a price point around R$ 3,627.82 per dose. What sets it apart is not just marketing—it's the way the drug engages with the body's chemistry.
Ozempic and Wegovy have become household names, but they are essentially the same medication: semaglutida, a compound that targets a single hormone pathway called GLP-1. This pathway tells the brain when the stomach is full. Ozempic, approved for diabetes, maxes out at 1 milligram per dose. Wegovy, marketed for weight loss, goes up to 2.4 milligrams. Both work, and both have generated enormous demand and cultural conversation. But Mounjaro operates on a different principle entirely. It is what researchers call a dual agonist—meaning it activates two separate hormone systems at once. The first is GLP-1, the same pathway the other drugs use. The second is GIP, a hormone that regulates insulin release when food enters the digestive system. By pulling both levers simultaneously, tirzepatida creates a different physiological effect.
The clinical evidence suggests this matters. A study published in JAMA Internal Medicine in July 2024 compared tirzepatida directly against semaglutida in patients carrying excess weight. The results favored Mounjaro across the board: higher percentages of total body weight lost, and more patients achieving what researchers classified as significant weight reduction. The difference was measurable and consistent. At the same time, another study in JAMA Ophthalmology raised a concern about the single-pathway drugs—both Ozempic and Wegovy appeared to carry some association with vision problems, a potential side effect that has not been as prominently documented with the dual-mechanism approach.
Dr. Melissa Barcellos Azevedo, who heads the endocrinology service at Hospital Mãe de Deus in Porto Alegre, clarifies the practical distinctions. Ozempic and Wegovy are interchangeable in terms of active ingredient; the choice between them depends on the condition being treated and the dose required. Mounjaro, by contrast, is a different drug class altogether. The prescribing logic differs too: Mounjaro and Ozempic are indicated for diabetes management, while Wegovy is positioned specifically for obesity without diabetes. This distinction matters for insurance coverage, physician training, and patient expectations.
What remains to be seen is how Brazilian patients and doctors will integrate this new option into an already crowded landscape. The arrival of Mounjaro does not displace the existing medications—it offers an alternative pathway, one with stronger early evidence for weight loss but also a different safety profile that will require ongoing monitoring. For endocrinologists, it expands the toolkit. For patients, it means another conversation with their doctor about which mechanism might work best for their particular body and condition. The real test will come not in the first months of availability, but in the years ahead, as long-term data accumulates and the full picture of who benefits most from which approach becomes clearer.
Citações Notáveis
Mounjaro is a dual agonist with capacity to bind to two different receptor types—GLP-1 and GIP—whereas Ozempic and Wegovy are single GLP-1 inhibitors— Dr. Melissa Barcellos Azevedo, endocrinologist at Hospital Mãe de Deus
Tirzepatida led to both higher percentages of body weight loss and more patients achieving significant weight reduction compared to semaglutida— JAMA Internal Medicine study, July 2024
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that Mounjaro hits two hormone systems instead of one?
Because the body doesn't work in isolation. GLP-1 tells you when you're full. GIP controls how your pancreas responds to food. By activating both, you're not just sending one signal—you're coordinating two different metabolic conversations at once. The studies show that coordination produces better weight loss results.
But Ozempic and Wegovy have already worked for millions of people. Why would someone switch?
They would if they're not seeing the results they want, or if they're diabetic and need something stronger. The evidence suggests Mounjaro gets people to their goals faster and more reliably. But it's not a magic difference—it's a measurable one.
What about the vision problems mentioned with Ozempic and Wegovy?
That's the unsettling part. A study flagged a potential link between those single-pathway drugs and vision complications. We don't yet know if Mounjaro carries the same risk. That's why doctors will be watching carefully as more people use it.
So this is still experimental in some sense?
Not experimental—it's approved and studied. But any new medication in a new market is being observed. The long-term safety data will come from real-world use. That's how we learn what actually happens when thousands of Brazilian patients take it over years, not months.
Will it be affordable for most people?
At R$ 3,627 per dose, it's expensive. That's a barrier for many. Insurance coverage and whether the government subsidizes it will determine who actually gets access. The price tag is real.